Profile data is unavailable for this security.
About the company
WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.
- Revenue in HKD (TTM)3.01bn
- Net income in HKD639.28m
- Incorporated2020
- Employees1.50k
- LocationWuXi XDC Cayman IncNo. 11 Xinhui Ring Road, Xinwu DistrictWUXI KY1-1104ChinaCHN
- Websitehttps://wuxixdc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 16.19bn | 10.78k | 6.62 | 1.03 | 5.63 | 1.53 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| Simcere Pharmaceutical Group Ltd | 6.82bn | -1.19bn | 17.31bn | 6.41k | -- | 2.35 | -- | 2.54 | -0.4532 | -0.4532 | 2.65 | 2.92 | 0.5198 | 2.19 | 2.64 | 970,421.30 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4721 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.06bn | 3.13bn | 18.28bn | 15.00k | 5.85 | 1.26 | 4.89 | 1.21 | 1.72 | 1.72 | 8.29 | 8.00 | 0.6578 | 3.30 | 5.67 | 1,004,211.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| China Medical System Holdings Ltd | 7.54bn | 1.49bn | 18.76bn | 5.78k | 12.57 | 1.09 | 10.82 | 2.49 | 0.6119 | 0.6119 | 3.08 | 7.08 | 0.384 | 2.89 | 5.65 | 1,322,918.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| Zai Lab Ltd | 2.77bn | -2.11bn | 22.54bn | 2.18k | -- | 3.93 | -- | 8.14 | -2.16 | -2.16 | 2.84 | 5.28 | 0.3507 | 3.11 | 7.77 | -- | -26.70 | -37.72 | -33.48 | -42.72 | 63.37 | 64.75 | -76.13 | -282.44 | 2.87 | -- | 0.1447 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| HUTCHMED (China) Ltd | 4.75bn | -326.66m | 24.32bn | 1.97k | -- | 4.22 | -- | 5.12 | -0.3887 | -0.3887 | 5.51 | 6.61 | 0.4775 | 7.10 | 4.15 | 2,391,330.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| WuXi XDC Cayman Inc | 3.01bn | 639.28m | 31.67bn | 1.50k | 50.27 | 4.91 | 43.50 | 10.53 | 0.5252 | 0.5252 | 2.66 | 5.38 | 0.5586 | 21.31 | 2.85 | 2,551,697.00 | 11.88 | -- | 15.43 | -- | 30.96 | -- | 21.27 | -- | 4.02 | -- | 0.0113 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| China Resources Pharmaceutical Group Ltd | 269.40bn | 4.06bn | 34.11bn | 72.76k | 8.40 | 0.656 | 2.74 | 0.1266 | 0.6461 | 0.6461 | 42.88 | 8.28 | 0.966 | 6.09 | 3.28 | 3,691,123.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Holder | Shares | % Held |
|---|---|---|
| Invesco Advisers, Inc.as of 16 Nov 2023 | 37.97m | 3.17% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 22.64m | 1.89% |
| UBS Asset Management (Singapore) Ltd.as of 16 Nov 2023 | 15.19m | 1.27% |
| UBS Asset Management (Hong Kong) Ltd.as of 27 Sep 2024 | 15.09m | 1.26% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 5.38m | 0.45% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 30 Sep 2024 | 5.12m | 0.43% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 3.41m | 0.28% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.34m | 0.20% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 445.00k | 0.04% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 430.00k | 0.04% |
